Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangu Shengwan is a traditional Chinese medicine (TCM) formulation developed and manufactured by Beijing Kuangda Pharmaceutical Factory. It is approved in China for the treatment of osteonecrosis, specifically avascular necrosis of the femoral head (ANFH). The formulation is composed of multiple active components, including *Radix Notoginseng*, *Radix Angelicae Sinensis*, *Pheretima*, *Cordyceps*, *Flos Croci*, *Margarita*, and *Borneolum Syntheticum*. Jiangu Shengwan exerts its therapeutic effects by promoting blood circulation, resolving blood stasis, dredging meridians, and nourishing blood to stimulate bone and cartilage repair. Clinical and experimental studies indicate that it helps alleviate joint pain and improve mobility, particularly in patients with early-stage femoral head necrosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangu Shengwan.